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Abstract 
Background: Alzheimer’s disease (AD) is the most common cause of dementia among the elderly and is character-
ized by loss of memory and other cognitive functions. An increase in AChE (a key enzyme in the cholinergic nervous 
system) levels around β-amyloid plaques and neurofibrillary tangles is a common feature of AD neuropathology. 
Amnesic effects of scopolamine (acetylcholine receptor antagonist) can be investigated in various behavioral tests 
such as Morris water maze, object recognition, Y-maze, and passive avoidance. In the scope of this paper, we report 
the anti-AChE, anti-BChE properties of the isolated compound and the in vivo effects of the methanolic extract of 
Xylia xylocarpa (MEXX) on scopolamine-induced memory deficit.
Results: In further phytochemistry study, a new hopan-type triterpenoid, (3β)-hopan-3-ol-28,22-olide (1), together 
with twenty known compounds were isolated (2–21). Compound 1, 2, 4, 5, 7–9, and 11–13 exhibited potent acetyl-
cholinesterase (AChE) inhibitory activity in a concentration-dependent manner with IC50 values ranging from 54.4 to 
94.6 μM. Compound 13 was also shown anti-butyrylcholinesterase (BChE) activity with an IC50 value of 42.7 μM. The 
Morris water Y-maze, Y-maze, and object recognition test were also carried out.
Conclusions: It is noteworthy that MEXX is effective when administered orally to mice, experimental results are con-
sistent with the traditional use of this medicinal plant species.
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Background
Alzheimer’s disease (AD), a degenerative brain disorder 
leading to dementia, is one of the most common disor-
ders of old age, affecting nearly 4 million individuals in 
the US. Typical clinical features of Alzheimer’s disease 
are memory loss, language deterioration, reduced visual 
space, sensation disorders and epilepsy advocacy gradual 
progression of terminal illness [1, 2]. There are several 
theories about the cause of Alzheimer’s disease, in which 
the theory about the decline of acetylcholine is the most 
widely accepted and is the basis for the current develop-
ment of the drugs of Alzheimer’s disease. The research 
on Alzheimer’s patients demonstrated that choliner-
gic abnormalities correlated with the degree of memory 
and cognitive impairment [2, 3]. These findings have led 
to the treatment of Alzheimer’s disease by increasing 
the activity of the cholinergic system (acetylcholinester-
ase, AChE, inhibitory mechanism) [2, 3]. Recently, some 
research found that AChE is also related to the formation 
of amyloid plaques and neurofibrillary tangles [4].
Xylia xylocarpa (Roxb.) Taub. is a perennial tree 
belonging to the family Fabaceae, which is sparsely dis-
tributed in Burma, Vietnam, Cambodia, and India. In 
Vietnam, X. xylocarpa is known as “Cam Xe”; the bark, 
heartwood, and flower have been used as Vietnamese 
traditional medicines for the treatment of dementia, duo-
denal, stomach pain, vomiting, diarrhoea, gonorrhoea, 
leprosy, and rheumatism [5]. Previously, the chemi-
cal constituents of the wood of X. xylocarpa have been 
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reported some flavan-3-ols including monomer, dimer, 
and trimer of epiafzelechin [6]. Our preliminary screen-
ing study also revealed that the methanolic extract of the 
wood of X. xylocarpa exhibited significant AChE and 
BChE (butyrylcholinesterase) inhibitory activities with 
IC50 values of 16.17 and 7.13 μg/mL, respectively. In the 
present study, we report the cognitive-enhancing effect of 
the methanolic extract of X. xylocarpa (MEXX) on amne-
sic mice induced by scopolamine in vivo. In addition, the 
isolation of MEXX was carried out, a new hopan-type 
triterpenoid, (3β)-hopan-3-ol-28,22-olide (1) was iso-
lated together with twenty known compounds (2–21). 
We also reported the anti-AchE, anti-BChE properties of 
the isolated compound herein.
Results and discussions
Chemistry
The MEXX was suspended in H2O and then successively 
partitioned with hexane, EtOAc, and BuOH to yield hex-
ane, EtOAc, BuOH and H2O fractions, respectively. Sepa-
ration and purification of EtOAc soluble fraction led to 
the isolation of a new hopan-ol-olide named (3β)-hopan-
3-ol-28,22-olide (1), together with twenty known com-
pounds (2–21). These known compounds were identified 
as lupeol (2) [7]; 28-norlup-20(29)-ene-3β,17β-diol (3) 
[8]; betulin (4) [9]; 28-norlup-20(29)-ene-3β-hydroxy-
17β-hydroperoxide (5) [10]; betulinaldehyde (6) [11]; bet-
ulinic acid (7) [12]; betulonic acid (8) [12]; oleanolic acid 
(9) [13]; 3β-hydroxy-18α-olean-28,19β-olide (10) [14]; 
3β-formyloxy-l8α-oleanano-28,19β-lactone (11) [15]; 
chrysophanol (12) [16]; 2,6-dimethoxyl-p-benzoquinone 
(13) [17]; ferulic acid (14) [18]; methyl ferulate (15) [19]; 
methyl 3-(4-hydroxyphenyl)-2-methoxycarbonylpro-
pionate (16) [20]; protocatechuic acid (17) [21]; vanillic 
acid (18) [22]; vanillin (19) [23]; methyl gallate (20) [24]; 
and syringic acid (21) [22] (Fig. 1) based on the spectro-
scopic analysis and comparison with literature data.
Compound 1 exhibited an [M + H]+ and [M + Na]+ 
peak at m/z 457.3674 and 479.3482, respectively, in the 
positive HR-ESI-MS, corresponding to the molecular for-
mula C30H48O3. The 13C NMR spectrum of compound 
1 showed thirty carbon signals, including one lactone 
carbonyl carbon (δC 175.9), one hydroxylated methine 
(δC 79.1), and one oxygenated tertiary carbon (δC 83.4). 
Together with the HSQC analysis, all the remaining car-
bon signals were identified as five methines, ten methyl-
enes, five quaternary carbons and seven tertiary methyl 
groups. The 1H NMR spectrum of compound 1 also 
exhibited an oxygenated methine proton signal at δH 3.19 
(dd, J = 11.4 and 4.8 Hz, H-3) and seven singlet methyl 
signals (δH 1.46, 1.33, 0.96, 0.94, 0.93, 0.83, 0.76). Based 
on the analysis of these spectra, compound 1 was sug-
gested to be an hopan-type triterpenoid [25, 26].
The location of hydroxyl group was deduced to be at 
C-3, based on the HMBC correlations between the oxy-
genated methine proton H-3 and the methylene car-
bon C-1 (δC 39.1). The HMBC cross-peaks from Me-23 
(δH 0.96) and Me-24 (δH 0.76) to the hydroxylated car-
bon C-3 (δC 79.1); and the splitting patterns of proton 
H-3 also indicated the hydroxyl group was attached to 
C-3. The ester carbonyl group was located at C-28 due 
to the HMBC correlations between the methine proton 
H-13/H-17 and the carbonyl carbon C-28. The tertiary 
methyl protons H-29 and H-30 exhibited simultaneously 
HMBC correlations with the oxygenated tertiary carbon 
(δC 83.4), these was carbon C-22. Based on the chemical 
shift of C-22 and C-28 [25], it is clear that the lactone ring 
was formed between these carbons. Combining the 1H- 
and 13C NMR data (Table 1) with the HSQC, COSY and 
HMBC analysis (Fig.  2), the skeletal structure of 1 was 
confirmed as a hopan-3-ol-28,22-olide. The proton H-3 
appeared as a doublet of doublets (δH 3.19, J = 11.4 and 
4.8 Hz) that indicating an axial position of this proton. In 
the NOESY spectrum (Fig. 2), the correlated signals were 
observed between H-3/equatorial H-2, H-3/H-5, H-3/
H-23 indicating that the 3-OH group was β-equatorial 
orientation. The NOESY spectrum also exhibited the cor-
relations of H-24/H-25, H-25/H-26, H-13/H-26, and H-9/
H-27; these observations confirmed four rings A, B, C, 
and D were trans-fused. The NOE correlations between 
H-13/H-17 and H-17/H-21 confirmed the β-equatorial 
orientation of H-21. Thus, the structure of compound 1 
was elucidated to be (3β)-hopan-3-ol-28,22-olide.
Biological assay
The isolated compounds were tested for their AChE 
and BChE inhibitory activities at various concentrations 
using berberin, a known inhibitor of AchE isolated from 
many plant species, as a positive control (Table 2). In the 
AChE inhibition assay, compounds 1, 2, 4, 5, 7–9, and 
11–13 showed the moderate activity on the inhibition of 
AChE with the IC50 values ranging from 54.4 to 94.6 μM, 
compared with berberine (IC50o of 0.67  μM). Regarding 
to the BChE inhibition, compound 13 showed the inhibi-
tory effects against BChE with an IC50 value of 42.7 μM, 
compared with the positive control berberine (IC50 of 
24.5 μM).
Since MEXX showed potent inhibition activity against 
ChE enzymes in the primary experiments with the IC50 
value of 16.17  μg/mL, the in  vivo effects of MEXX on 
scopolamine-induced memory deficit were investigated 
by using the Y-maze task. A significant group effect was 
observed in spontaneous alternation behaviors [F (4, 
55) = 10.859, P < 0.001]. Spontaneous alternation (%) in 
the scopolamine-treated group was significantly lower 
than that in the vehicle-treated control group (Fig.  3a, 
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P  <  0.001), and this spontaneous alternation reduction 
was significantly ameliorated following MEXX admin-
istration (100  mg/kg, p.o.) (Fig.  3a, P  <  0.01). However, 
the mean numbers of the arm entries were similar in all 
experimental groups (Fig.  3b), which demonstrated that 
locomotor activity was not affected by MEXX.
Next, the effect of MEXX (50, 75 or 100  mg/kg, 
p.o.) on spatial learning was evaluated using the Mor-
ris water maze task. A repeated measures two-way 
ANOVA revealed that there were significant group 
effects for days [F (4.099, 45.088) =  46.944, P  <  0.001], 
[F (3.788, 41.666)  =  31.557, P  <  0.001] and treatment 
groups [F (2.408, 26.483) = 34.871, P < 0.001], [F (3.555, 
39.106)  =  45.942, P  <  0.001] on training-trial escape 
latencies and swimming distances, respectively. As 
shown in Fig. 2, the scopolamine-treated group (1.5 mg/
kg, i.p.) exhibited longer escape latencies and swimming 
distances than did vehicle-treated controls from days 3 
to 7 (Fig. 4a, b; P < 0.01 and P < 0.001). MEXX (50 mg/
kg, p.o.) reduced escape latencies on day 5 (P < 0.05), day 
6 (P  <  0.01), day 7 (P  <  0.001) and swimming distances 
on day 6 (P < 0.01), day 7 (P < 0.001) when compare to 
scopolamine-treated group. In addition, MEXX (75 mg/
kg, p.o.) reduced escape latencies on day 4 (P < 0.05), day 
5 (P < 0.01), day 6, 7 (P < 0.001) and swimming distances 
on day 5 (P  <  0.01) day 6, 7 (P  <  0.001) when compare 
to scopolamine-treated group. Finally, MEXX (100  mg/
kg, p.o.) reduced escape latencies on day 4 (P < 0.01), day 
5, 6, 7 (P  <  0.001) and swimming distances on day 4, 5 
(P < 0.01) day 6, 7 (P < 0.001) when compare to scopol-
amine-treated group. On the last day (day 8), the time in 
the target quadrant in scopolamine treated mice was sig-
nificantly reduced compared to that of the vehicle-treated 
controls (Fig. 4c, P < 0.05). Furthermore, the shorter time 
in the target quadrant induced by scopolamine was sig-
nificantly reduced by MEXX (100  mg/kg, p.o.) (Fig.  4c, 
P < 0.05).
As shown in Fig.  5a, there was no significant differ-
ence in locomotor activities determined as total distance 
travel between vehicle-treated control, Scop 1.5 mg, and 
XX mice groups. Administrations of MEXX (50, 75 or 
100  mg/kg, p.o.) before the experiments had no effect 
on locomotor activity compared with those in the vehi-
cle-treated control. In the sample experiment, no mouse 
Fig. 1 Chemical structures of isolated compounds (1–21) from the wood of X. xylocarpa
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groups showed significant differences in time spent 
exploring each identical object (Fig.  5b). On the other 
hand, the control and XX 100 mg groups spent a signifi-
cantly longer time exploring the new object than explor-
ing the familiar one (P < 0.01 paired t test), while the XX 
50 mg and XX 75 mg groups mouse showed a deficit in 
terms of the novel object recognition performance in the 
test phase session, as shown in Fig. 5c.
In this study, scopolamine significantly reduced spon-
taneous alternation (%) in Y-maze test and time exploring 
the new object in object recognition test in scop 1.5 mg 
group mice. These indicated that scopolamine induces 
impairment of short-term spatial and non-spatial work-
ing memory. In Morris water maze test, scopolamine 
impaired gradual decrease of escape latencies, swim-
ming distances during training session and reduced 
the time spent in target quadrant during probe session. 
These observations suggest that scopolamine not only 
impairs the process of acquisition by producing antero-
grade amnesia, which subsequently affects the retrieval 
of these. Morris water maze test represents the model of 
memory especially spatial memory. During the training 
trials, mouse locates the hidden platform using spatial 
cues. This model is very helpful to analyze the rever-
sal amnesic effect with investigational drug because 
Table 1 1H and  13C NMR data for  (3β)-hopan-3-ol-28,22-
olide (1) in CDCl3
Position (3β)-Hopan-3-ol-28,22-olide (1)
δC, type δH (J in Hz)
1a 39.1, CH2 1.62, m
1b 1.72, m
2 27.6, CH2 1.61, m
3 79.1, CH 3.19, dd (11.4, 4.8)
4 41.0, C –
5 55.6, CH 0.69, m
6 18.5, CH2 1.56, m
7 34.2, CH2 1.39, m
8 41.8, C –
9 50.9, CH 1.38, m
10 37.4, C –
11 20.6, CH2 1.51, m
12 27.0, CH2 1.62, m
13 37.1, CH 1.79, m
14 41.8, C –
15a 33.8, CH2 1.82, m
15b 1.59, m
16a 26.5, CH2 2.00, m
16b 1.61, m
17 48.3, CH 1.62, m
18 48.7, C –
19a 29.1, CH2 2.41, dt (13.3, 3.5)
19b 1.25–1.30, m
20 29.1, CH2 1.25, m
21 42.6, CH 2.13, t (4.4)
22 83.4, C –
23 28.2, CH3 0.96, s
24 15.9, CH3 0.76, s
25 16.4, CH3 0.83, s
26 15.5, CH3 0.93, s
27 14.2, CH3 0.94, s
28 175.9, C –
29 30.3, CH3 1.46, s
30 30.4, CH3 1.32, s
Fig. 2 The selected 1H-1H COSY, HMBC and NOESY correlations of 1
Table 2 Cholinesterase inhibitory activity of  the isolated 
compounds








AChE BChE AChE BChE
1 79.5 ± 1.1 >100 11 86.5 ± 0.6 >100
2 75.7 ± 3.1 >100 12 77.3 ± 0.8 >100
3 >100 >100 13 54.4 ± 3.4 42.7 ± 7.6
4 93.4 ± 2.2 – 14 >100 >100
5 83.9 ± 0.6 >100 15 >100 –
6 – – 16 >100 >100
7 62.0 ± 2.2 – 17 >100 –
8 94.6 ± 1.5 >100 18 >100 >100
9 84.9 ± 1.2 >100 19 >100 –
10 >100 – 20 >100 –
Berberine 0.67 ± 0.0 24.5 ± 0.2 21 >100 –










































Fig. 3 The effects of MEXX on scopolamine-induced memory impairment in mice in the Y-maze task. Spontaneous alternation behavior (a) and 
numbers of arm entries (b) during a 10 min session were recorded. Data represent mean ± SEM (n = 12 per group) (***P < 0.001 versus the vehicle-
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Fig. 4 The effects of MEXX on escape latencies (a), and swimming distance (b) during the training-trial sessions and on swimming times during the 
probe-trial session (c) in the Morris water maze task on scopolamine induced memory dysfunction in mice. Data represent mean ± SEM (n = 12 per 
group) (*P < 0.05, **P < 0.01, ***P < 0.001 versus the vehicle-treated controls, ##P < 0.01, ###P < 0.001 versus the scopolamine-treated group)
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receptive trials with ongoing trials confirm the progress 
of reversal of amnesia [27–29].
In our experiment, administration of MEXX plus sco-
polamine-treated groups showed significantly shorter 
mean escape latencies and swimming distances than did 
the scopolamine-treated group in training session. The 
swimming time of the scopolamine-treated mice within 
the platform quadrant was significantly reduced by 
treating with MEXX (100 mg/kg) in probe session. This 
indicated that MEXX is able to protect mice from sco-
polamine-induced learning and memory (both acquisi-
tion and retrieval process) impairment as assessed by the 
Morris water maze test. The in  vitro inhibitory activity 
on AChE and BChE of MEXX suggesting that the in vivo 
memory enhancing effect of MEXX due to its AChE inhi-
bition in cells and tissues. The results are in correlations 
with those of previous studies on the effect of memory 
enhancing of some natural product such as: Black Maca, 
imperatorin, Lycium barbarum polysaccharides [27, 
30–32].
Working memory is one of the short-term memo-
ries that could be impaired at an early stage of AD [2, 
29]. Previous reports have shown that Y-maze test is the 
experimental paradigms appropriate to evaluate anti-
dementia activities of drugs including natural products 
[29, 33]. Some plants exhibit the inhibitory activity on 
AChE reduced spontaneous alternation (%) in Y-maze 
test [27, 34]. In our experiment, we employed Y-maze test 
to investigate effect of MEXX in short-term spatial work-
ing memory. The experimental results showed MEXX 
(100  mg/kg) improved scopolamine-induced decrease 
in spontaneous alternation (%) while it did not affect in 
spontaneous locomotors. This suggests that MEXX alle-
viated the memory impairment induced by scopolamine 
injection.
The effect of the MEXX on cognitive impairment was 
further confirmed by using object recognition test [35]. 
According to the results, no significant difference in total 
time spent exploring two identical objects was observed 
between control and scop 1.5 mg groups in sample phase 
session, indicating no differences in ability to recognize 
objects between animals. In the test phase session, the 
results showed that mice in the control group spent more 
time exploring the new object, whereas the scopolamine-
treated mice showed no total time difference between 
familiar and new objects, indicating impairment of non-
spatial object recognition memory. Administration of 
MEXX (100  mg/kg, p.o.) could significantly ameliorate 
scopolamin-induced recognition impairment against the 
new objects. This result is in correlation with other stud-
ies on Ptychopetalum olacoides [33], Acanthopanax trifo-




































































Object 1 Object 2
Fig. 5 Effects of MEXX on object recognition deficits in mice in the sample phase (b) and the test phase (c), while data of locomotor activities are 
shown in (a). Each datum represents mean ± SEM (n = 12). The **P < 0.01 versus time spent exploring a familiar object (paired t test)
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AChE activity and improved performance in object rec-
ognition test in scopolamine treated mice.
Previous authors indicated that performance in 
Y-maze, object recognition task are impaired by anti-
cholinergic drugs, as well as cholinergic neuronal 
lesions [32, 37, 38]. Conversely, improved performance 
in Y maze, object recognition was observed with drugs 
that enhance cholinergic activity, and inhibit AChE [27, 
30]. Alzheimer’s treatment drug such as piracetam and 
pramiracetam, were shown to improve learning, memory 
and cognition in Morris water maze, Y-maze and object 
recognition test [38]. Our results are consistent with 
the notion that acetylcholine is critical in the processes 




The UV spectra were obtained with a Shimadzu UV-1800 
recording spectrophotometer. The IR spectra were 
measured with a Shimadzu IR-408 spectrophotometer 
in CHCl3 solutions. The NMR spectra were taken on a 
Bruker Avance III 500  MHz spectrometer (Bruker Bio-
spin) with tetramethylsilane (TMS) as an internal stand-
ard, and chemical shifts are expressed in δ values. The 
HR-ESI-MS was performed on a MicrO-QIITOF mass 
spectrometer (Bruker Daltonics). The ChE inhibitory 
reactions were recorded on 96-well microplates using a 
microplate reader (VersaMax ELISA, USA). Silica gel 60, 
0.06–0.2  mm (70–230 mesh ASTM), for column chro-
matography was purchased from Scharlau (Barcelona, 
Spain). LiChroprep® RP-18 (40–63  μm) for liquid chro-
matography was purchased from Merck KGaA (Ger-
many). Analytical and preparative TLC were carried out 
on precoated Merck Kieselgel 60F254 or RP-18F254 plates 
(0.25 or 0.5 mm thickness).
Animals and chemicals
Male Swiss mice (age, 8 weeks; weight, 25–27 g) were pur-
chased from Military Medical University (Hanoi, Vietnam) 
and housed in a regulated environment (21 ± 2  °C, 12 h 
light/dark cycle, light period starting at 7 AM) with free 
access to food and water. Acetylcholinesterase (AChE) 
(EC 3.1.1.7), butyrylcholinesterase (BChE) (EC 3.1.1.8) and 
scopolamine hydrobromide (>98  %) were obtained from 
Sigma-Aldrich Pte Ltd (Nucleos, Singapore). Dithiobis-
nitrobenzoate (>99 %), berberine (>95 %) and DMSO were 
purchased from Merck (Darmstadt, Germany). Other 
chemicals were of the highest grade available.
Plant material
The wood of X. xylocarpa was collected in Dak Lak prov-
ince, Vietnam, in February 2012 and was identified by 
Dr. Truong LH, Southern Institute of Ecology, Vietnam 
Academy of Science and Technology. A voucher sample 
of the wood (P0046) has been deposited at the Depart-
ment of Analytical Chemistry, Faculty of Chemistry, 
University of Science, Vietnam National University-
Hochiminh City.
Extraction and isolation
Dried wood (9.0 kg) of X. xylocarpa was extracted with 
MeOH (15 L, reflux, 3  h ×  3) to yield 480  g of metha-
nolic extract (MEXX). The MeOH extract was suspended 
in H2O and partitioned successively with hexane, EtOAc, 
and BuOH to yield hexane (21  g), EtOAc (53  g), BuOH 
(180 g), and remaining aqueous (226 g) fractions, respec-
tively. The EtOAc fraction (53 g) was subjected to silica 
gel column chromatography (10 × 120 cm), eluted with 
MeOH/CHCl3 (0–50 %) yielding thirteen fractions (fr.A, 
0.4  g; fr.B, 0.5  g; fr.C, 0.9  g; fr.D, 7.8  g; fr.E, 2.1  g; fr.F, 
3.2  g; fr.G, 1.9  g; fr.H, 1.9  g; fr.I, 1.2  g; fr.J, 0.3  g; fr.K, 
4.1 g; fr.L, 7.8 g and fr.M, 20.5 g). Fraction fr.B (0.5 g) was 
applied to silica gel column chromatography (2 × 80 cm), 
eluted with EtOAc/hexane (0–80  %) to give four sub-
fractions (fr.B1–B5). Subfractions fr.B2 and fr.B3 were 
rechromatographed on a silica gel column with EtOAc/
hexane as eluent to give compounds 2 (17.6 mg), and 12 
(2.4  mg). Fraction fr.C (0.7  g) was also subjected to sil-
ica gel column chromatography (2 × 80 cm), eluted with 
EtOAc/hexane (0–80 %) to afford three subfractions (fr.
C1–C3). Subfraction fr.C1 was separated by column 
chromatography with EtOAc/hexane as eluent (0–60 %) 
and purified by preparative TLC to obtain 5 (3.5  mg) 
and 6 (6.3  mg). Subfraction fr.C2 was further sepa-
rated by silica gel column chromatography, eluted with 
EtOAc/hexane and CHCl3/hexane to give compound 11 
(2.6  mg). Fraction fr.D (7.8  g) was dissolved in CHCl3/
hexane (20:80) to gain the precipitation of 10 (2.4 g), the 
remaining part was further separated by silica gel col-
umn chromatography (5  ×  80  cm) with EtOAc/hexane 
(0–80 %) to yield four subfractions (fr.D1–D4). Subfrac-
tion fr.D1 was rechromatographed on silica gel column 
chromatography with EtOAc/hexane to give 3 (2.8  mg) 
and 8 (3.1 mg). Subfraction fr.D3 was subjected to silica 
gel column chromatography and successively eluted with 
acetone/hexane (0–80  %), EtOAc/CHCl3 (0–50  %), ace-
tone/CHCl3 (0–80 %), and then followed by preparative 
TLC with acetone/hexane (8:92) to afford 1 (15.7 mg), 4 
(19.3 mg) and 9 (3.2 mg). Fraction fr.E (2.1 g) was sepa-
rated by silica gel column chromatography (3 ×  80 cm) 
with MeOH/CHCl3 (0–30  %) as eluent to yield four 
subfractions (fr.E1–E4). Subfractions fr.E1 and fr.E2 
were purified by preparative TLC with EtOAc/hexane 
(20:80) and acetone/hexane (6:94) to yield 13 (14.6 mg), 
14 (5.8  mg) and 15 (10.2  mg). Subfraction fr.E3 was 
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further separated by silica gel column chromatography 
with MeOH/CHCl3 to give four subfraction (fr.E3.1–
E3.4). Subfraction fr.E3.1 was rechromatographed on a 
silica gel column with EtOAc/hexane as eluent (0–60 %) 
to afford compound 16 (5.6 mg). The insoluble subfrac-
tion fr.E3.4 was dissolved in acetone/hexane (10:90) and 
recrystallized to yield 18 (15.9 mg). Fraction fr.F (3.2 g) 
was further separated by silica gel column chromatogra-
phy (3 × 80 cm) eluted with EtOAc/hexane (0–50 %) and 
MeOH/CHCl3 (0–30 %) and to give 19 (3.6 mg). Fraction 
fr.G (1.9 g) was subjected to silica gel column chromatog-
raphy (3 ×  80  cm) eluted with MeOH/CHCl3 (0–60  %) 
to give four subfractions (fr.G1–G4). Subfraction fr.G1 
and fr.G2 was rechromatographed on silica gel column 
with EtOAc/hexane and CHCl3/hexane and respectively 
purified by preparative TLC with acetone/CHCl3 (10:90) 
and MeOH/CHCl3 (10:90) to give 7 (156.3  mg) and 
21 (3.5  mg), respectively. Compound 19 (160  mg) was 
recrystallised from the insoluble fraction of fr.I (1.2  g) 
in acetone/hexane (10:90), and the remaining part was 
applied to silica gel column chromatography (2 × 80 cm) 
with MeOH/CHCl3 as eluent (0–50  %), the eluate was 
concentrated and crystallised in acetone/hexane (10:90) 
to afford 17 (10.2 mg).
(3β)-Hopan-3-ol-28,22-olide (1): White amophous 
powder, IR (CHCl3) cm−1: 3310, 1730, 1170, 1100. 
1H-NMR (CDCl3, 500  MHz) and 13C-NMR (CDCl3, 
125  MHz), see Table  1. HR-ESI-MS m/z: 457.3674 
[M + H]+ and 479.3482 [M + Na]+ (Calcd for C30H49O3, 
457.3682; C30H48O3Na, 479.3501) (for further informa-
tion, see Additional file 1).
AChE and BChE inhibition assay
The inhibitory activities of the ChEs were measured 
using a modified Ellman’s method [39]. Acetylthiocho-
line and butyrylthiocholine were used as substrates to 
examine the inhibitory effect of sample on the AChE 
and BChE action, respectively. The reaction mixture 
contained: 140 μL of sodium phosphate buffer (pH 8.0); 
20  μL of tested sample solution; and 20  µL of either 
AChE or BChE solution (5  units/mL), which were 
mixed and incubated at room temperature for 15  min. 
The reactions were initiated by the addition of 10  µL 
of dithiobisnitrobenzoate (DTNB) and 10  μL of either 
acetylthiocholine or butyrylthiocholine, respectively. The 
hydrolysis of AChE or BChE was monitored at 412  nm 
based on the formation of yellow 5-thio-2-nitrobenzo-
ate anion from the reaction of DTNB with thiocholine, 
which was released by enzymatic hydrolysis of either 
AChE or BChE. All tested samples and the positive con-
trol, berberine [40], were dissolved in 10 % DMSO (ana-
lytical grade). The reaction was performed in triplicate 
and recorded in 96-well microplates using a microplate 
reader (VersaMax ELISA, USA). Percent inhibition was 
calculated from (1–S/E) × 100, where E and S were the 
enzyme activities with and without the tested sample, 
respectively. The ChE inhibitory activity of each sample 
was expressed in terms of the IC50 value (μM required to 
inhibit the hydrolysis of the substrate, AChE or BChE, by 
50 %), as calculated from the logarithmic dose-inhibition 
curve.
Animal grouping and drug treatment
The male Swiss mice were randomly assigned to five 
treatment groups (n = 12 per group): (1) Control (Saline), 
(2) Scop 1.5  mg (scopolamine 1.5  mg/kg/day), (3) XX 
50 mg (MEXX 50 mg/kg/day + scopolamine 1.5 mg/kg/
day), (4) XX 75 mg (MEXX 75 mg/kg/day + scopolamine 
1.5 mg/kg/day) and (5) XX 100 mg (MEXX 100 mg/kg/
day + scopolamine 1.5 mg/kg/day). MEXX was dissolved 
in saline and administered by oral gavage (p.o.). Scopol-
amine was also dissolved in saline and administered by 
intraperitoneal (i.p.) injection. MEXX was administered 
60  min before the trial, and scopolamine was injected 
30 min before the trial.
Morris water Y-maze test
The Morris water maze is a black circular pool (80 cm in 
diameter and 35  cm in height) with a featureless inner 
surface. The circular pool was filled with water and non-
toxic water-soluble black dye (20 ± 1  °C). The pool was 
divided into four quadrants of equal area. A transpar-
ent platform (4 cm in diameter and 18 cm in height) was 
centered in one of the four quadrants of the pool and 
submerged 1  cm below the water surface so that it was 
invisible at water level. The pool was located in a test 
room, which contained various prominent visual cues. 
The position of platform for escape and the visual cues 
remained unchanged throughout the experiments. The 
location of each swimming mouse, from the start posi-
tion to the platform, was monitored by a video tracking 
system (ANY-maze, Stoelting, USA). In the water maze 
experiments, the day prior to the experiment was dedi-
cated to swim training for 60 s in the absence of the plat-
form. During the seven subsequent days, the mice were 
given four training-trials per session per day and an inter-
trial interval of 2 min. For each training-trial, mice were 
placed in the water facing the pool wall in a randomly 
selected pool quadrant, the escape latencies and distance 
swim were recorded. These parameters were averaged for 
each day and for each mouse. Once the mouse located 
the platform, it was permitted to remain on it for 10  s. 
If the mouse did not locate the platform within 60  s, it 
was placed on the platform for 10  s and then removed 
from the. On day 8, the probe test involved removing the 
platform from the pool. That test was performed with 
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the cut-off time of 120 s. The point of entry of the mouse 
into the pool was changed each trial thereafter. Mice 
were treated with saline or MEXX (50, 75 or 100 mg/kg, 
p.o.) given before the training trial. After 30 min, amnesia 
was induced in mice with scopolamine (1.5 mg/kg) given 
intraperitoneal injection. All mice were tested for spatial 
memory 30 min after scopolamine treatment.
Y-maze test
The Y-maze is a three-arm maze with equal angles 
between all arms, which were 35  cm length and 5  cm 
width, with walls 10 cm high. The maze floor and walls 
were constructed from dark grey polyvinyl plastic. Mice 
were initially placed within one arm, and the sequence 
and number of arm entries were recorded 10-min period 
for each mouse and analyzed monitored by a video track-
ing system (ANY-maze, Stoelting, USA). One hour before 
the test, mice in control group and scop 1.5  mg group 
received distilled water and other mice were adminis-
tered MEXX (50, 75, or 100 mg/kg, p.o.). After 30 min, 
memory impairment was induced by administering sco-
polamine (1.5  mg/kg, i.p.). Arms were cleaned between 
tests to remove odors and residues by diluted 10 % etha-
nol. Alternation behavior was determined from succes-
sive entries into three different arms (e.g., ABC, CAB, or 
BCA). An arm entry by the mice was defined as placing 
all four paws within a boundary of the arm. The alterna-
tion score (%) for each mouse was defined as the ratio of 
the actual number of alternations to the possible number 
(defined as the total number of arm entries minus two) 
multiplied by 100 as shown by the following equation: 
% Alternation  =  [(Number of alternations)/(Total arm 
entries − 2)] × 100. The number of arm entries was used 
as an indicator of locomotor activity.
Object recognition test
The task took place in a to an open-field box 
(45 × 45 × 50 cm). Firstly, all animals were submitted to a 
habituation session, freely exploring the object free open 
field for 5 min. Twenty-four hours later, the sample phase 
session took place by placing individual mice for 5 min at 
the field in which two identical objects (A1 and A2; iden-
tical toys) were placed in a symmetrical position about 
10 cm away from the wall; exploration was defined as the 
time spent sniffing or touching the object with the nose 
and/or forepaws. Test phase session were performed 24 h 
after training, when mice were allowed to explore the 
open field for 5 min in the presence of one familiar (A) 
and one novel (B) object. One hour before test phase ses-
sion, mice were administered MEXX (50, 75, or 100 mg/
kg, p.o.). The control group received distilled water. After 
30 min, memory impairment was induced by administer-
ing scopolamine (1.5  mg/kg, i.p.). All objects presented 
similar textures and sizes, but distinctive shapes; after 
each trial objects were washed with 10 % ethanol to dis-
card smells or residues. The exploration time and fre-
quencies were recorded, n = 12 per group.
Statistical analysis
The results of the behavioral studies are expressed as 
mean ±  SEM, Y-maze test spontaneous alternation (%), 
object recognition test distance travel and Morris water 
maze test probe-trial swimming times were analyzed 
by one-way analysis of variance (ANOVA) followed by 
Tukey’s post hoc for multiple comparisons. The object 
recognition test time spent exploring a familiar and 
novel object in sample and test phase were analyzed by 
pair t-test. The Morris water maze test training-trial 
escape latencies and distance were analyzed by two-way 
ANOVA repeated followed by Tukey’s post hoc analysis 
using the day as one variable and treatment as a second. 
Statistical significance was set at P < 0.05.
Conclusions
In conclusion, a new hopan-type triterpenoid, (3β)-
hopan-3-ol-28,22-olide (1) was isolated together with 
twenty known compounds (2–21). Compound 1, 2, 4, 
5, 7–9, and 11–13 exhibited potent acetylcholinesterase 
(AChE); and compound 13 was also shown anti-butyryl-
cholinesterase (BChE) activity. The cognitive-enhancing 
effect of the MEXX on amnesic mice induced by sco-
polamine in vivo. It is noteworthy that MEXX is effective 
when administered orally to mice, experimental results 
are consistent with the traditional use of this medici-
nal plant species, the data here reported justify further 
studies with this plant extract in the context of treating 
attention and cognitive deficits associated with neurode-
generative diseases.
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